论文部分内容阅读
目的评价伊立替康(CPT-11)联合顺铂(DDP)方案治疗晚期非小细胞肺癌(NSCLC的疗效和不良反应。方法由国内4家医院协作研究完成。人组晚期NSCLC患者36例中,初次化疗24例,曾经化疗12例;全部患者均有可测量或可评价的指标。给药方法:CPT-11 60 mg／m2静脉滴注,第1、8、15天;DDP 80 mg/m2静脉滴注,第1天;28 d为1个周期。结果36例患者共接受治疗97个周期,中位数为3个周期。可评价病例数为35例,无CR病例,PR 8例(22．9％),SD 21例(60．0％),PD 6例(17．1％)。初治者有效率为29．2％(7／24),复治者有效率为9．1％(1／11),中位治疗至进展时间为199 d,1年生存率为45．4％。Ⅲ、Ⅳ度不良反应发生率为粒细胞减少(16．7％),脱发(13．9％),腹泻(5．6％),恶心呕吐(2．8％)。结论CPT-11联合DDP方案对晚期NSCLC治疗有效,患者耐受性良好,应进行深入研究。
Objective To evaluate the efficacy and adverse reactions of irinotecan (CPT-11) combined with cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC) .Methods A total of 36 patients with advanced NSCLC were enrolled in this study, The first chemotherapy in 24 cases, chemotherapy in 12 cases, all patients have measurable or measurable indicators. Methods of administration: CPT-11 60 mg / m2 intravenous drip, on the 1st, 8th, 15th day; DDP 80 mg / m2 Intravenous drip on day 1 and 28 days for 1 cycle.Results 36 patients were treated for 97 cycles with a median of 3 cycles.The number of evaluable cases was 35 cases without CR and 8 cases with PR 22.9%), SD 21 cases (60.0%) and PD 6 cases (17.1%). The effective rate of the primary treatment was 29.2% (7/24) and that of the retreatment was 9%. 1% (1/11) .The median time to progression was 199 days, and the 1-year survival rate was 45.4%. The incidence of grade Ⅲ and Ⅳ adverse reactions were neutropenia (16.7%), hair loss (13% .9%), diarrhea (5.6%) and nausea and vomiting (2.8%) .Conclusion The CPT-11 combined with DDP regimen is effective in the treatment of advanced NSCLC and its patients should be well tolerated.